Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Tartarone, Alfredo ^a   Lerose, Rosa ^a   Lazzari, Chiara ^b   Gregorc, Vanesa ^b   Aieta, Michele ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Afatinib; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MUTATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84902921465     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0078-5     Document Type: Review

References (31)

1. Somaiah N, Simon NG, Simon GR. A tabulated summary of targeted and biologic therapies for non small cell lung cancer. J Thorac Oncol. 2012;16(Suppl 5):S342-68.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-39. (Pubitemid 38637993)
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500. (Pubitemid 38720929)
4. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-67.
5. Kwak E, Bang YL, Camidge RD, et al. Anaplastic lymphoma kinase inhibition in non small cell lung cancer. N Engl J Med. 2010;363:1693-703.
6. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;823-59.
7. Peters S, Adjei AA, Gridelli C. Metastatic non small cell lung cancer: ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii56-64.
8. Patel JD, Krilow L, Adams S, et al. Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2014;32:129-60.
9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
10. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122-8.
11. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase III trial. Lancet Oncol. 2010;11:121-8.
12. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-8.
13. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;8:735-42.
14. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutationpositive non small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46.
15. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342-50.
16. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non small cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncol. 2014;15:213-22.
17. Bria E, Milella M, Cuppone F, et al. Out come of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22:2277-85.
18. Keating GM. Afatinib: a review of its use in the treatment of advanced non small cell lung cancer. Drugs. 2014;74:207-21.
19. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor higly effective in preclinical lung cancer models. Oncogene. 2008;27:4702-11.
20. Leveque D. Pharmacokinetics of gefitinib and erlotinib. Lancet Oncol. 2011;12:1093.
21. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13:539-48.
22. Liang W, Wu X, Fang W. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non small cell lung cancer harboring EGFR mutations. PLoS ONE. 2014;9(2):e85245.
23. Katakami N, Morita S, Yoshioka H et al. Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. J Clin Oncol 2014; 32:5 s, 2014 ASCO Annual Meeting (abstr 8041).
24. Kim ST, Uhm JE, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer. 2012;75:82-8.
25. Wu JY, Wu SG, Yang CH, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer. 2011;72:205-12.
26. Liang W, Sheng J, Wu X et al. Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: a meta-analysis of subgroup data from eight phase III randomized controlled trials. J Clin Oncol 2014; 32:5 s, 2014 ASCO Annual Meeting (abstr 8107).
27. Yang JCH, Sequist LV, Schuler MH et al. Overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 and LUX-Lung 6) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014; 32:5 s, 2014 ASCO Annual Meeting (abstr 8004∧).
28. Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non small cell lung cancer on 10117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25:126-31.
29. Yang JCH. Sequist LV, Geater SL et al. Activity of afatinib in uncommon epidermal growth factor receptor mutations: findings from three prospective trials of afatinib in EGFR mutations positive. WLCL 2013; abstr 003.05.
30. Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and out come in non small cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78:8-15.
31. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342-50.